Boston Family Office LLC Takes Position in Enanta Pharmaceuticals Inc (ENTA)

Boston Family Office LLC bought a new stake in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) during the first quarter, Holdings Channel reports. The institutional investor bought 2,750 shares of the biotechnology company’s stock, valued at approximately $263,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Municipal Employees Retirement System of Michigan bought a new stake in shares of Enanta Pharmaceuticals during the 4th quarter worth about $405,000. Chicago Equity Partners LLC boosted its stake in shares of Enanta Pharmaceuticals by 16.5% during the 4th quarter. Chicago Equity Partners LLC now owns 32,379 shares of the biotechnology company’s stock worth $2,293,000 after acquiring an additional 4,590 shares in the last quarter. KBC Group NV boosted its stake in shares of Enanta Pharmaceuticals by 95.2% during the 4th quarter. KBC Group NV now owns 41,421 shares of the biotechnology company’s stock worth $2,934,000 after acquiring an additional 20,198 shares in the last quarter. Deutsche Bank AG boosted its stake in shares of Enanta Pharmaceuticals by 125.4% during the 4th quarter. Deutsche Bank AG now owns 76,836 shares of the biotechnology company’s stock worth $5,440,000 after acquiring an additional 42,744 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Enanta Pharmaceuticals by 30.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,426,791 shares of the biotechnology company’s stock worth $121,934,000 after acquiring an additional 330,374 shares in the last quarter. Hedge funds and other institutional investors own 86.07% of the company’s stock.

Enanta Pharmaceuticals stock opened at $94.45 on Friday. The company has a market capitalization of $1.86 billion, a price-to-earnings ratio of 27.14 and a beta of 1.30. Enanta Pharmaceuticals Inc has a 12 month low of $64.08 and a 12 month high of $127.77.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported $0.20 EPS for the quarter, beating the consensus estimate of ($0.09) by $0.29. The firm had revenue of $39.60 million during the quarter, compared to analysts’ expectations of $40.92 million. Enanta Pharmaceuticals had a return on equity of 19.25% and a net margin of 33.28%. The company’s revenue for the quarter was down 10.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.61 EPS. Equities research analysts expect that Enanta Pharmaceuticals Inc will post 1.9 earnings per share for the current year.

ENTA has been the subject of several recent analyst reports. BidaskClub upgraded Enanta Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, May 9th. Berenberg Bank upgraded Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and increased their target price for the company from $80.00 to $120.00 in a research note on Tuesday, April 23rd. Zacks Investment Research downgraded Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, January 25th. Finally, Wolfe Research initiated coverage on Enanta Pharmaceuticals in a research note on Friday. They set an “outperform” rating and a $117.00 target price for the company. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $114.83.

In other Enanta Pharmaceuticals news, VP Yat Sun Or sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $103.53, for a total value of $1,035,300.00. Following the completion of the transaction, the vice president now owns 304,763 shares of the company’s stock, valued at approximately $31,552,113.39. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Bruce L. A. Carter sold 1,546 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $99.16, for a total value of $153,301.36. Following the completion of the transaction, the director now directly owns 1,546 shares of the company’s stock, valued at approximately $153,301.36. The disclosure for this sale can be found here. In the last ninety days, insiders sold 20,826 shares of company stock valued at $2,150,473. Insiders own 11.35% of the company’s stock.

WARNING: “Boston Family Office LLC Takes Position in Enanta Pharmaceuticals Inc (ENTA)” was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.com-unik.info/2019/05/25/boston-family-office-llc-takes-position-in-enanta-pharmaceuticals-inc-enta.html.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.

See Also: Why are gap-down stocks important?

Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals Inc (NASDAQ:ENTA).

Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit